Navigation Links
Seahorse Bioscience and the Cancer Research UK Beatson Institute Team Up Against Cancer

BILLERICA, Mass., Aug. 22, 2013 /PRNewswire/ -- Seahorse Bioscience will provide the Cancer Research UK Beatson Institute with its novel XF technology, which measures cell metabolism, to boost research to enable a greater understanding of cancer metabolism and its role in disease progression.

The recently named Director of the Beatson Cancer Metabolism Research Unit, Eyal Gottlieb, Ph.D., will lead the research which will focus on understanding key aspects of cancer cell behavior using the Seahorse XFe96 Extracellular Flux Analyzer.

"My lab combines analytical chemistry, cell biology, and biochemical approaches to study metabolic transformation. These technologies are not only important for understanding the basic biochemistry of cancer cells, but can also inform us on future clinical management of cancer, and may lead to new therapeutic approaches to target cancer-specific metabolic pathways," stated Dr. Gottlieb.

Cancer researchers have a renewed interest in cancer cells' abnormal metabolism of sugar, known as the Warburg effect.  Even though oxygen rich conditions favor using the more efficient metabolic pathway via mitochondrial respiration, many cancer cells rely on glycolysis.  This is thought to enhance their survival as most solid tumors and their metastases experience periods of low oxygen (hypoxia), where glycolysis is their only source of energy.  This reliance on glycolysis promotes both tumor progression and resistance to therapy.  These factors and an understanding of the role mitochondria play in regulating cancer growth have stimulated new approaches to deter cancer proliferation.  The Seahorse XFe Analyzer is the only analytical instrument that can measure active switching between the two energy pathways critical to cancer cell metabolism:  glucose metabolism and mitochondrial respiration - and can do so under hypoxic conditions in real-time.

"Using the XFe96 Analyzer will enable me to decipher the different pathways of cancer cell metabolism, particularly under hypoxic conditions, which I believe is a key to new therapeutic strategies," added Dr. Gottlieb. "Once I realized that I could measure the dynamics of cancer metabolism in real-time, in a hypoxic environment, I knew we needed this technology." 

"Whenever we are able to bring together the best minds with enabling technologies we know that good things will come of it. Innovative scientific collaborations play a crucial role in finding ways to unlock the potential of new therapies, and the Beatson Institute has a strong heritage of research excellence in cancer research," said David Ferrick, Ph.D., Chief Scientific Officer at Seahorse Bioscience.  "We are excited to work with the Beatson Institute, and hope that in utilizing the power of the XF Analyzer they will gain greater understanding and potentially new discoveries regarding cancer metabolism." 

Naomi Goumillout
Marketing Communications Manager
Seahorse Bioscience

About Seahorse Bioscience
Seahorse XF instruments are the standard in cellular bioenergetic measurements. More than 700 scientists in 23 countries are utilizing the award-winning XF Analyzers to advance their research into the role of cell metabolism and its implications in cancer, aging, and metabolic, cardiovascular, and neurodegenerative diseases.  Seahorse is headquartered in Billerica, MA.  For more information, visit

About the Beatson Institute for Cancer Research
As one of Cancer Research UK's core-funded institutes, the Beatson Institute for cancer Research carries out a program of world-class science directed at understanding key aspects of cancer cell behavior, and tries to translate these discoveries into new therapies and diagnostic/prognostic tools to help cancer patients. The Institute benefits from close interactions with the University of Glasgow, including strong links with the University's Institute of Cancer Sciences. For more information contact the Cancer Research UK press office on 020 3469 8352, or visit

SOURCE Seahorse Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Launches Reagent to Make Functional Fatty Acid Oxidation (FAO) Assays Easy
2. Seahorse Bioscience Ranks No. 1600 on the Inc. 500
3. 5000 List of Fastest-Growing Private Companies in America for 2012 with Three-Year Sales Growth of 183%
4. Seahorse Bioscience Launches First Product from the Partnership with Baystate Medical Center and UMass Amherst
5. Seahorse Bioscience Announces AACR Travel Award Recipients
6. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
(Date:11/27/2015)... CHESTERFIELD, United Kingdom , Nov. 27, 2015 /PRNewswire/--  ... specialty biopharmaceutical company, announced today that it has closed ... systems (CMDS) business to Guerbet (GBT- NYSE Euronext) in ... CMDS operations encompassed four manufacturing facilities and a total ... nearly 75 in the St. Louis ...
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
(Date:11/25/2015)...  PharmAthene, Inc. (NYSE MKT: PIP) announced  today that ... plan (Rights Plan) in an effort to preserve the ... Section 382 of the Internal Revenue Code (Code). ... of its NOLs could be substantially limited if the ... 382 of the Code. In general, an ownership change ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
Breaking Biology News(10 mins):